CAS 2023788-19-2 API

GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids.

CAS: No.2023788-19-2

Batch Size:32 MT / Year

Production Capacity:28 KG / Batch

Documentation:FDA-Approved GMP /US DMF /WC /NDC